Published in Cancer Res on August 01, 1993
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 4.07
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 3.44
Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest (1998) 3.01
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol (2008) 2.21
Retracted Novel management of oral cancer: a paradigm of predictive oncology. Clin Med Res (2004) 2.14
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia (2006) 1.81
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Nano-bio-chip sensor platform for examination of oral exfoliative cytology. Cancer Prev Res (Phila) (2010) 1.76
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer (1996) 1.66
Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett (2007) 1.62
Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147. Cancer Biol Ther (2008) 1.57
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol (2013) 1.57
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer (2011) 1.45
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Global expression-based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. Neoplasia (2006) 1.44
Molecular pathogenesis of oral squamous carcinoma. Mol Pathol (2000) 1.44
Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia (2009) 1.42
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2003) 1.30
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.26
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets (2010) 1.25
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol (2009) 1.19
Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol (2005) 1.18
ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17
Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother (2010) 1.15
Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer (1994) 1.15
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol (2011) 1.13
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol (2006) 1.13
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol (2008) 1.12
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) (2010) 1.10
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer (2011) 1.10
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst (2014) 1.09
TGFβ signaling in head and neck squamous cell carcinoma. Oncogene (2010) 1.08
Targeting EGFR resistance networks in head and neck cancer. Cell Signal (2009) 1.07
Tautomerism in drug discovery. J Comput Aided Mol Des (2010) 1.05
Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A (2005) 1.05
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther (2014) 1.05
Molecular targeted therapies in head and neck cancer--an update of recent developments-. Head Neck Oncol (2010) 1.03
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn (2010) 1.03
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res (2013) 1.02
Cetuximab: its unique place in head and neck cancer treatment. Biologics (2013) 1.01
Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer (2008) 1.01
Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer Res (2011) 0.99
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer (2011) 0.97
NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. Toxicol Appl Pharmacol (2013) 0.97
Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma. BMC Cancer (2009) 0.95
Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer (2010) 0.95
Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia (2011) 0.94
XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res (2011) 0.93
Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol (2013) 0.93
New advances in molecular approaches to head and neck squamous cell carcinoma. Anticancer Drugs (2011) 0.93
Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. Int J Cancer (2013) 0.92
Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res (2008) 0.92
In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. Sci Rep (2015) 0.91
Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biol Med (2016) 0.91
Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer (2010) 0.91
Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene (2013) 0.91
Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther (2012) 0.91
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol (2007) 0.91
Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther (2013) 0.90
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther (2012) 0.90
The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α. Cancer Lett (2012) 0.90
Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One (2012) 0.90
PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. Oncotarget (2015) 0.89
Lessons learned from next-generation sequencing in head and neck cancer. Head Neck (2012) 0.88
Oral field cancerization: current evidence and future perspectives. Oral Maxillofac Surg (2012) 0.88
Patterns of expressions of transforming growth factor and epidermal growth factor receptor in squamous cell lesions of the urinary bladder. J Clin Pathol (1998) 0.88
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol (2012) 0.87
HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res (2014) 0.86
Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol (2011) 0.86
Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer (2011) 0.86
Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia. Br J Cancer (2013) 0.86
Expression of epidermal growth factor receptor in the inverted papilloma and squamous cell carcinoma of nasal cavity. Eur Arch Otorhinolaryngol (2008) 0.86
A cell-targeted photodynamic nanomedicine strategy for head and neck cancers. Mol Pharm (2013) 0.85
Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res (2010) 0.85
Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex. Cancer Res (2013) 0.84
Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol (2014) 0.84
Emerging strategies for the early detection and prevention of head and neck squamous cell cancer. J Cell Physiol (2012) 0.83
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer (2013) 0.83
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis (2014) 0.83
Lentiviral vector-based therapy in head and neck cancer (Review). Oncol Lett (2013) 0.83
High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients. Cell Commun Signal (2014) 0.82
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer. J Signal Transduct (2011) 0.82
Biomolecular markers in cancer of the tongue. J Oncol (2009) 0.82
Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck. J Oncol (2012) 0.81
Glottic versus supraglottic tumors: differential molecular profile. Eur Arch Otorhinolaryngol (2007) 0.81
Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature. Acta Otorhinolaryngol Ital (2006) 0.81
Sphingosine kinase 1 mediates head & neck squamous cell carcinoma invasion through sphingosine 1-phosphate receptor 1. Cancer Cell Int (2014) 0.81
Epigenetic modulation of signal transduction pathways in HPV-associated HNSCC. Otolaryngol Head Neck Surg (2013) 0.81
Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol (2013) 0.81
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (1998) 5.05
Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest (1998) 3.01
Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol (1987) 2.54
Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . Prostate (2000) 2.03
Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. J Exp Med (1998) 1.96
Essential role for IL-6 in postresuscitation inflammation in hemorrhagic shock. Am J Physiol Cell Physiol (2001) 1.81
Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis. J Antimicrob Chemother (1983) 1.56
Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. Proc Natl Acad Sci U S A (1994) 1.42
Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood (1996) 1.29
Interleukin-6 production in hemorrhagic shock is accompanied by neutrophil recruitment and lung injury. Am J Physiol (1998) 1.17
Association of altered dynamics of monocyte surface expression of human leukocyte antigen DR with immunosuppression in tuberculosis. J Infect Dis (1984) 1.16
FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. Transplant Proc (1991) 1.15
Spectrum of immunoregulatory functions and properties of human alveolar macrophages. Am Rev Respir Dis (1987) 1.13
TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl (1993) 1.13
Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res (1998) 1.11
Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst (1998) 1.08
Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene (1997) 1.07
Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med (1996) 1.07
A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. Transplantation (1993) 1.05
Molecular cloning, characterization, and tissue distribution of rat lipopolysaccharide binding protein. Evidence for extrahepatic expression. J Immunol (1994) 1.02
Lectin-induced apoptosis of tumour cells. Glycobiology (1993) 1.02
A novel nitric oxide scavenger decreases liver injury and improves survival after hemorrhagic shock. Am J Physiol (1999) 1.00
Molecular and functional contractile sequelae of rat intestinal ischemia/reperfusion injury. Transplantation (1999) 0.98
Induction of hepatocyte lipopolysaccharide binding protein in models of sepsis and the acute-phase response. Arch Surg (1993) 0.97
Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med (1999) 0.97
Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem (1998) 0.96
G-CSF instillation into rat lungs mediates neutrophil recruitment, pulmonary edema, and hypoxia. J Leukoc Biol (1998) 0.95
Cytokine induction of interferon regulatory factor-1 in hepatocytes. Surgery (1993) 0.95
Establishment and characterization of an undifferentiated human T leukemia cell line which requires granulocyte-macrophage colony stimulatory factor for growth. J Immunol (1987) 0.94
Hemorrhagic shock induces G-CSF expression in bronchial epithelium. Am J Physiol (1997) 0.93
Hypoxia-inducible factor-1 activation and cyclo-oxygenase-2 induction are early reperfusion-independent inflammatory events in hemorrhagic shock. Arch Orthop Trauma Surg (2001) 0.93
Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT3 in human neutrophils. J Leukoc Biol (1998) 0.92
Stat3 and G-CSF-induced myeloid differentiation. Leuk Lymphoma (1998) 0.91
Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium. Clin Cancer Res (1998) 0.91
Concurrent enhancement of monocyte immunoregulatory properties and effector functions by recombinant interferon-gamma. Cell Immunol (1986) 0.90
Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele. Hum Immunol (1994) 0.90
Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock. Shock (2000) 0.89
Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia. Leukemia (1998) 0.89
IL-6 produced by Kupffer cells induces STAT protein activation in hepatocytes early during the course of systemic listerial infections. J Immunol (1998) 0.88
Impaired gut contractility following hemorrhagic shock is accompaied by IL-6 and G-CSF production and neutrophil infiltration. Dig Dis Sci (2001) 0.88
TCR-gamma genes are rearranged but not transcribed in IL-7R alpha-deficient mice. J Immunol (1997) 0.88
Granulocyte colony-stimulating factor (G-CSF) production in hemorrhagic shock requires both the ischemic and resuscitation phase. Arch Orthop Trauma Surg (1997) 0.87
Primary listerial infections are exacerbated in mice administered neutralizing antibody to macrophage colony-stimulating factor. J Immunol (1992) 0.87
Identification and characterization of cis elements in the STAT3 gene regulating STAT3 alpha and STAT3 beta messenger RNA splicing. Blood (2001) 0.86
HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies. Hum Immunol (1995) 0.86
Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line. Int J Oncol (1998) 0.85
Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer. Cancer (1992) 0.85
Rapid and simultaneous activation of Stat3 and production of interleukin 6 in resuscitated hemorrhagic shock. Arch Orthop Trauma Surg (1999) 0.84
Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta. Oncogene (2006) 0.83
Induced nitric oxide inhibits IL-6-induced stat3 activation and type II acute phase mRNA expression. Shock (2000) 0.83
Bacteriophages are synergistic with bacterial interference for the prevention of Pseudomonas aeruginosa biofilm formation on urinary catheters. J Appl Microbiol (2012) 0.82
Activation of STAT proteins in the lung of rats following resuscitation from hemorrhagic shock. Arch Orthop Trauma Surg (1998) 0.82
Interleukin-6 infusion blunts proinflammatory cytokine production without causing systematic toxicity in a swine model of uncontrolled hemorrhagic shock. J Trauma (2004) 0.82
Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood (1999) 0.82
Failure of immunosuppressive mechanisms in human Schistosoma mansoni infection with hepatosplenomegaly. J Clin Microbiol (1987) 0.82
Evidence that production of interleukin 6 within the rejecting allograft coincides with cytotoxic T lymphocyte development. Transplantation (1991) 0.81
Modulation of human G-CSF receptor mRNA and protein in normal and leukemic myeloid cells by G-CSF and retinoic acid. J Leukoc Biol (1995) 0.81
Activation of STAT proteins following ischemia reperfusion injury demonstrates a distinct IL-6 and G-CSF mediated profile. Transplant Proc (1998) 0.78
Human granulocyte colony-stimulating factor (G-CSF), the premier granulopoietin: biology, clinical utility, and receptor structure and function. Lymphokine Cytokine Res (1993) 0.77
The role of peptide growth factors in head and neck carcinoma. Otolaryngol Clin North Am (1992) 0.77
Reduced hepatic transcription factor activation and expression of IL-6 and ICAM-1 after hemorrhage by NO scavenging. Arch Orthop Trauma Surg (2003) 0.77
Granulocyte-macrophage colony-stimulating factor augmentation of T-cell receptor-dependent and T-cell receptor-independent thymocyte proliferation. Blood (1994) 0.76
Substance P receptor antagonist reverses intestinal pathophysiological alterations occurring in a novel ex-vivo model of Cryptosporidium parvum infection of intestinal tissues derived from SIV-infected macaques. J Med Primatol (2008) 0.76
Making sense of the combined effect of interleukin-2 and interleukin-4 on lymphocytes using a mathematical model. Bull Math Biol (1996) 0.76
Abnormalities of immunosuppression in patients with hepatosplenic schistosomiasis mansoni. Trans Assoc Am Physicians (1983) 0.76
Augmentation of TNF cytotoxicity by protein kinase C inhibitors: role of arachidonic acid and manganese superoxide dismutase. Cytokine (1995) 0.76
A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells. J Exp Med (1986) 0.75
Efficacy of topical amoxicillin plus clavulanate/ticarcillin plus clavulanate and clindamycin in contaminated head and neck surgery: effect of antibiotic spectra and duration of therapy. J Infect Dis (1994) 0.75
Enhancement of monocyte immunoregulatory properties and effector functions by recombinant interferon-gamma. Trans Assoc Am Physicians (1984) 0.75
FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. J Surg Res (1992) 0.75
Cytokine products of T-helper 2 (Th2) cells are present in rejecting sponge matrix allografts. Transplant Proc (1991) 0.75
Function of hematopoietin receptor subunits in hepatic cells and fibroblasts. Ann N Y Acad Sci (1995) 0.75
Increased blastogenic responses to worm antigen and loss of adherent suppressor cell activity after treatment for human infection with Schistosoma mansoni. J Infect Dis (1985) 0.75
Delineation and mapping of Stat5 isoforms activated by granulocyte colony-stimulating factor in myeloid cells. Blood Cells Mol Dis (2000) 0.75
Proliferation and differentiation of human myelogenous leukemia and preleukemia cells in culture: identification of stimulatory and suppressor growth factors. Haematologica (1988) 0.75
Proto-oncogene transcription after activation of Th-1 and Th-2 cells. Ann N Y Acad Sci (1991) 0.75
Relapsing toxic shock syndrome in the puerperium. JAMA (1985) 0.75
Identification of a novel protein capable of interacting with the IL-3 receptor. J Immunol (1991) 0.75
Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. Blood (1993) 0.75